logo

  • HOME
  • BUSINESS
  • Life Science

Life Science

OCI Holdings is taking a major leap forward as a leading global pharmaceutical·bio company based on an “Acquisition & Development (A&D)” strategy targeting specialized leading technologies.

Life Science

OCI Holdings promotes a strategic approach to expanding the pharmaceutical·BIO business as the future growth engine.

We launched our bio business in 2018 to develop innovative new drugs and treatments based on global partnerships with advanced biotechnology companies and investors.

We are making investments in promising biotech ventures with next-generation cancer diagnosis and anti-cancer treatment pipelines and have achieved tangible results.

In February 2022, we secured the position of the largest shareholder in Bukwang Pharmaceutical Co., Ltd., a leading R&D-centric pharmaceutical company in Korea, and are now operating under a joint management structure.

CompanyMajor projectsInvestment amount
Bukwang Pharmaceutical Co., Ltd. (Korea)A fully integrated biopharmaceutical companyKRW 146.1 billion
SN BioScience
(Korea)		Nanoparticle-based
targeted drug delivery system		KRW 5 billion
Panolos
Bioscience
(Korea)		Multi-specific
recombinant protein		KRW 5 billion
Adicet* (USA)Allogenic
cancer immunology cell therapy		USD
7.8 million
Nucleix (Israel)Early diagnosis of cancerUSD
5.5 million
Synergy fund (Korea)Bio ventures in
new drug and medical device		KRW 3 billion

* Adicet : listed on NASDAQ in September 2020 as Adicet Bio after merger with resTORbio, a bio company listed on NASDAQ

R&D in pharmaceuticals

Global network establishment and new drug pipeline development

반도체용 폴리실리콘
Production of pharmaceuticals

Commercializing bioproducts at home and abroad, CMO

의약품 연구 개발
Business marketing

Building solid partnerships, strategic response to markets

의약품 연구 개발
Bukwang Pharmaceutical
부광약품
Based on an open innovation model for new drug development through strategic investment and collaboration with external partners, Bukwang Pharmaceutical Co., Ltd. has expanded the range of its pipelines in the fields of CNS and oncology. The company currently has global partnerships with more than 30 overseas pharmaceutical companies.
Website